Enterococcus Faecalis: Infections, Causes, and Treatment

Enterococcus faecalis is a bacterium that normally lives quietly in the human gut but can cause serious infections when it reaches places it does not belong, such as the bloodstream, heart valves, urinary tract, or the inside of a tooth. It ranks among the leading causes of hospital-acquired infections worldwide, and its natural toughness against several common antibiotics makes those infections harder to treat than many people expect. Understanding how this organism shifts from harmless gut resident to dangerous pathogen, and why standard antibiotics often fall short, matters for anyone navigating a diagnosis involving E. faecalis.

A Normal Gut Resident That Can Turn Dangerous

The name itself is a clue: “entero” refers to the intestine, and “faecalis” to feces. E. faecalis was first isolated in the early 1900s and belongs to a genus of more than 50 species that colonize the digestive tracts of insects, birds, reptiles, and mammals, including humans.¹ In a healthy adult gut, E. faecalis is subdominant, meaning it is present but kept in check by the larger community of bacteria around it. A key reason for that suppression appears to be bile acids. The bile acid deoxycholate, which is abundant in a balanced gut, slows E. faecalis growth and forces the bacterium to constantly adjust its gene expression just to survive.²

Trouble starts when that balance is disrupted. Broad-spectrum antibiotics are the most common trigger: they wipe out large swaths of the normal bacterial community while leaving resistant enterococci behind, allowing E. faecalis to multiply densely in the gut.¹ When bile acid profiles shift during this disruption, with deoxycholate dropping and taurocholate rising, the chemical brake on E. faecalis growth is released.² An overgrown gut population then becomes a reservoir from which the organism can spread to other body sites, especially in hospitalized patients with catheters, surgical wounds, or weakened immune defenses.

Who Is Most at Risk

Enterococcal bloodstream infections are overwhelmingly associated with healthcare settings. In a large population-based study of 710 enterococcal bloodstream episodes, about 80% were either hospital-acquired or healthcare-associated, leaving only roughly one in five as truly community-acquired.³ Men faced about double the risk compared to women, and people aged 70 or older had a dramatically higher incidence. The same study identified a long list of underlying conditions that raised risk:

Cancer: gastrointestinal, genitourinary, and blood cancers in particular
Kidney disease: especially in patients on dialysis
Gastrointestinal conditions: peptic ulcer disease, inflammatory bowel disease
Cardiovascular disease: heart disease, stroke, hypertension
Diabetes and autoimmune conditions: including rheumatoid arthritis

Hospitalization itself is a major driver. Indwelling catheters, intravenous lines, and prolonged antibiotic courses all open doors for E. faecalis to enter the bloodstream or colonize devices. Patients in intensive care units face especially high risk because they tend to have multiple invasive devices and receive broad-spectrum antibiotics that reshape the gut flora in exactly the way E. faecalis exploits.

Catheter-Associated Urinary Tract Infections

E. faecalis is one of the leading causes of catheter-associated urinary tract infections (CAUTIs), which account for a huge share of hospital-acquired infections globally. What makes these infections distinctive is that the catheter itself is doing much of the work. In mouse models, when researchers introduced E. faecalis into bladders without a catheter, the bacteria triggered minimal inflammation and were rapidly cleared. But with a catheter in place, the silicone tubing provoked an intense inflammatory response, and E. faecalis thrived in that environment, forming biofilms on the catheter surface and colonizing the bladder at high levels.⁴

The mechanism involves a surface structure called the Ebp pilus, a tiny fiber that E. faecalis uses to grab onto fibrinogen, a protein the body deposits on catheter surfaces as part of the inflammatory response.⁵ In other words, the body’s own wound-healing response to the foreign device creates the very attachment points the bacterium needs. Making matters worse, E. faecalis can suppress the local immune response in the bladder, dialing down the macrophage activity that would normally fight infection. This immune suppression does not just help E. faecalis itself; it can also allow other bacteria, including normally harmless strains of E. coli, to establish urinary infections they otherwise could not.⁶

Infective Endocarditis

E. faecalis is now recognized as one of the leading causes of infective endocarditis worldwide, an infection of the heart’s inner lining and valves that carries a high mortality rate.⁷ The patients affected tend to be older and medically fragile, often with pre-existing valve abnormalities or prosthetic heart valves. The bacteria circulating in the blood settle on damaged or artificial valve surfaces, forming vegetations, which are clumps of bacteria embedded in blood-clotting material. These vegetations can grow large enough to be seen on echocardiography, and pieces can break off and travel to other organs. In one reported case, a septic embolus from a mitral valve vegetation caused acute coronary syndrome, essentially mimicking a heart attack.⁸

Treatment of enterococcal endocarditis is particularly challenging because it requires prolonged antibiotic courses, typically four to six weeks, and sometimes surgical valve replacement. The treatment details are covered further below.

Bloodstream Infections and Mortality

When E. faecalis enters the blood, the resulting bacteremia can be life-threatening. In a retrospective study of 768 enterococcal bloodstream episodes, E. faecalis was the most common species, accounting for about 56% of cases. Sepsis or septic shock was present in nearly half of episodes, and the overall 30-day mortality rate was 19%.⁹ A separate study found that appropriate antibiotic therapy substantially reduced the odds of death, while ICU admission, low platelet counts, and chronic liver failure all raised mortality risk.¹⁰

Two factors consistently emerge as protective in the research: getting an infectious diseases consultation early and starting appropriate antibiotics within 48 hours. In the large cohort study, infectious diseases consultation within 48 hours roughly halved the risk of death, and timely source control, meaning removing or draining the focus of infection, was one of the strongest predictors of survival.⁹ One in five patients with E. faecalis bloodstream infections may also have endocarditis lurking underneath, which is why guidelines generally recommend echocardiography when enterococcal bacteremia is confirmed.¹¹

Root Canal Failures and Dental Infections

Outside the hospital, the place you are most likely to encounter E. faecalis clinically is in a dentist’s chair. The bacterium is the primary pathogen associated with failed root canal treatments, showing up in somewhere between 24% and 77% of persistent endodontic infections depending on the study.¹² Several traits make E. faecalis uniquely suited to surviving inside a treated tooth: it can invade the tiny tubules within dentin, tolerate long periods without nutrients, and withstand the alkaline environment created by calcium hydroxide, a disinfectant commonly used during root canal procedures.¹³

Its ability to form biofilms inside root canals is a central part of the problem. Biofilm-embedded bacteria are vastly more resistant to both antibiotics and disinfection agents than free-floating cells, and research continues to emphasize that enhanced disinfection methods and anti-biofilm strategies are needed to improve retreatment outcomes.¹⁴

What Makes It So Hard to Kill

E. faecalis has both built-in and acquired defenses against antibiotics, and understanding the difference matters for treatment decisions.

On the built-in side, E. faecalis is intrinsically resistant to cephalosporins, an entire class of antibiotics that hospitals rely on heavily. This resistance depends on a signaling pathway involving a membrane-bound enzyme called IreK, which senses when the cell wall is under attack and activates protective responses.¹⁵ A partner protein, GpsB, boosts IreK’s activity, amplifying this defense.¹⁶ Because this resistance is hardwired into the chromosome rather than carried on mobile genetic elements, it is universal in the species. No E. faecalis strain is susceptible to cephalosporins under normal conditions, which is why these drugs are never used to treat enterococcal infections.

Acquired resistance is a different and evolving concern. Vancomycin-resistant E. faecalis (VRE) has emerged through the acquisition of gene clusters such as vanB, carried on mobile genetic elements called transposons that can hop between bacteria.¹⁷ Other resistance gene clusters like vanE sit on the chromosome and confer low-level vancomycin resistance.¹⁸ Vancomycin resistance remains more common in E. faecium than in E. faecalis, but hospital outbreaks of vancomycin-resistant E. faecalis do occur and are a serious clinical event when they do.

High-level aminoglycoside resistance is another acquired problem that directly affects treatment. Aminoglycosides like gentamicin are traditionally paired with ampicillin for synergistic killing of enterococci. But when E. faecalis carries genes encoding aminoglycoside-modifying enzymes, that synergy is lost. In one hospital survey, roughly 40% of E. faecalis and E. faecium isolates carried the gene responsible for high-level gentamicin resistance.¹⁹

Then there is the biofilm problem. Even when E. faecalis is susceptible to an antibiotic in its free-floating form, the same strain growing in a biofilm can tolerate drug concentrations far higher than what the body can safely achieve. In laboratory testing, biofilms of E. faecalis survived concentrations above 128 micrograms per milliliter for every antibiotic tested, including ampicillin, vancomycin, daptomycin, linezolid, and tetracycline, even though the planktonic cells were killed at standard doses.²⁰ This is why infections involving implanted devices or damaged tissue, where biofilms form, are so much harder to eradicate with drugs alone and often require physical removal of the infected device.

How Infections Are Treated

For serious E. faecalis infections, particularly endocarditis and complicated bloodstream infections, international guidelines recommend combination therapy with ampicillin plus a synergistic partner for four to six weeks.²¹ The traditional synergistic partner was gentamicin, an aminoglycoside that helps ampicillin penetrate the bacterial cell. However, gentamicin carries substantial kidney and hearing toxicity, especially over the weeks-long courses needed for endocarditis.

This toxicity concern, combined with the rising prevalence of high-level aminoglycoside resistance, has driven a shift toward the double beta-lactam combination of ampicillin plus ceftriaxone. This pairing works because the two drugs bind to different targets on the bacterial cell wall, producing a synergistic killing effect without the kidney damage associated with gentamicin. Ampicillin plus ceftriaxone is now considered first-line therapy for severe E. faecalis infections.²² Importantly, the ceftriaxone in this combination is not being used to kill the enterococcus directly (remember, E. faecalis is intrinsically resistant to cephalosporins). Instead, it saturates certain cell-wall binding sites that ampicillin alone cannot fully occupy, enhancing ampicillin’s bactericidal effect.

For patients who cannot tolerate beta-lactams or who have vancomycin-resistant strains, alternatives include daptomycin and linezolid. Daptomycin has shown rapid bactericidal activity against E. faecalis at achievable drug levels, while linezolid tends to be bacteriostatic, meaning it stops bacterial growth but does not reliably kill the organism.²³ The choice between them depends on the infection site, the resistance profile of the strain, and the patient’s overall condition.

How It Evades the Immune System

Beyond antibiotic resistance, E. faecalis has evolved ways to dodge the immune system that help explain why infections persist even in patients with intact immunity. Some strains produce a capsular polysaccharide, essentially a sugar coating on the cell surface, that interferes with the body’s ability to flag and consume the bacteria through a process called opsonophagocytosis. Research has shown that encapsulated strains are more resistant to being eaten by immune cells called macrophages. The capsule does not prevent the body’s complement proteins from binding to the bacterial surface; instead, it physically masks those bound proteins so that immune cells cannot detect them.²⁴

Virulence factors like gelatinase, aggregation substance, and surface proteins further help the bacterium damage tissues and establish infection. In one analysis, the genes for gelatinase and aggregation substance were more prevalent in E. faecalis than in the related species E. faecium, and both genes were associated with stronger biofilm formation.²⁵ This partly explains why E. faecalis, despite being more often susceptible to antibiotics than E. faecium, still causes such persistent and serious infections: it compensates with a deeper toolbox of virulence traits.

Phage Therapy and Emerging Approaches

With resistance narrowing the antibiotic options, researchers have been exploring bacteriophages, viruses that infect and kill bacteria, as a potential weapon against E. faecalis. While phage cocktails targeting E. faecalis are not commercially available in the EU or the United States, laboratory and animal evidence has been accumulating.²⁶ One phage, designated EFDG1 and isolated from sewage, showed effective killing of various E. faecalis and E. faecium strains regardless of their antibiotic resistance profiles. It also disrupted biofilms and, in an experimental model, prevented E. faecalis colonization of root canals.²⁷

The dental application is particularly interesting because root canal infections are localized and accessible, making them a plausible early target for phage-based treatments. However, phage therapy faces regulatory hurdles that antibiotics passed decades ago, and clinical trials in humans are still in early stages. For now, phages remain a research tool rather than a treatment option your doctor can prescribe.

The Food Chain and Environmental Reservoirs

E. faecalis is not confined to hospital corridors. Surveillance studies have consistently found the bacterium, often carrying resistance genes, on food animal carcasses and in environmental samples. A decade-long Korean study testing over 3,400 E. faecalis isolates from cattle, pig, and chicken carcasses found that chicken-derived strains had the highest resistance rates, with over 40% resistant to ciprofloxacin, erythromycin, and tetracycline.²⁸ Aminoglycoside and tetracycline resistance genes have been found in E. faecalis from human, animal, and environmental sources alike, suggesting that resistance determinants circulate freely across these boundaries.²⁹

The concern is that antibiotic-resistant enterococci contaminating meat during slaughter can reach humans through the food chain. While cooking kills the bacteria, cross-contamination in kitchens and the possibility of ingesting viable organisms means that agricultural antibiotic practices have direct implications for the resistance patterns clinicians face in hospitals. This is why E. faecalis is increasingly discussed in “One Health” frameworks that treat human, animal, and environmental health as interconnected rather than separate domains.

How Laboratories Identify the Organism

Accurate species-level identification of enterococci matters clinically because E. faecalis and E. faecium have different resistance profiles and require different treatment approaches. Traditional biochemical tests can distinguish the two, but newer technologies have improved both speed and accuracy. A technology called MALDI-TOF mass spectrometry, now standard in many hospital labs, identifies bacteria by their protein fingerprint within minutes of a colony appearing on a culture plate. Comparative studies have found it performs well for common enterococcal species, though whole-genome sequencing offers superior accuracy, particularly for unusual or closely related species, and its cost continues to drop.³⁰

Genomic sequencing is also increasingly used not just for identification but for tracking resistance genes and tracing outbreak clusters within hospitals. By comparing the genetic fingerprints of strains from different patients, infection-control teams can determine whether an outbreak involves a single circulating strain or multiple independent introductions, a distinction that changes how aggressively contact precautions and environmental cleaning are deployed.